Dr. Mink Chawla

So in medicine, physiology is our North Star. And from a data level, it's randomized controlled trial data. And it should be. Okay. Let's be very clear. I'm not deviating from this position whatsoever. The problem is RCT level data that shows you something you can do to help somebody is not available for many, many patients.

So in medicine, physiology is our North Star. And from a data level, it's randomized controlled trial data. And it should be. Okay. Let's be very clear. I'm not deviating from this position whatsoever. The problem is RCT level data that shows you something you can do to help somebody is not available for many, many patients.

So in medicine, physiology is our North Star. And from a data level, it's randomized controlled trial data. And it should be. Okay. Let's be very clear. I'm not deviating from this position whatsoever. The problem is RCT level data that shows you something you can do to help somebody is not available for many, many patients.

If you have chronic Lyme, if you have chronic whatever, the modern medical RCT level data does not offer you very much. And long COVID is in that spot. There's a few RCTs that suggest maybe SSRIs can deal with symptomology, but none of it is dealing with the core problem, whatever it is.

If you have chronic Lyme, if you have chronic whatever, the modern medical RCT level data does not offer you very much. And long COVID is in that spot. There's a few RCTs that suggest maybe SSRIs can deal with symptomology, but none of it is dealing with the core problem, whatever it is.

If you have chronic Lyme, if you have chronic whatever, the modern medical RCT level data does not offer you very much. And long COVID is in that spot. There's a few RCTs that suggest maybe SSRIs can deal with symptomology, but none of it is dealing with the core problem, whatever it is.

So my thesis, this is now hypothesis, is that spike protein and spike protein products or consequences like amyloid are largely responsible for what we call long COVID syndrome. I don't think everyone with long COVID has a spike protein problem, but I think many of them do.

So my thesis, this is now hypothesis, is that spike protein and spike protein products or consequences like amyloid are largely responsible for what we call long COVID syndrome. I don't think everyone with long COVID has a spike protein problem, but I think many of them do.

So my thesis, this is now hypothesis, is that spike protein and spike protein products or consequences like amyloid are largely responsible for what we call long COVID syndrome. I don't think everyone with long COVID has a spike protein problem, but I think many of them do.

We really think that's a real possibility.

We really think that's a real possibility.

We really think that's a real possibility.

Because like I said, the clinical trial that you're going to be in is, is, is set up and we're looking to expand it farther. And, you know, we think this could really make an impact for folks. Look, we have had people under an IRB, this is under a formal IRB program under compassionate use with long COVID, get the filter.

Because like I said, the clinical trial that you're going to be in is, is, is set up and we're looking to expand it farther. And, you know, we think this could really make an impact for folks. Look, we have had people under an IRB, this is under a formal IRB program under compassionate use with long COVID, get the filter.

Because like I said, the clinical trial that you're going to be in is, is, is set up and we're looking to expand it farther. And, you know, we think this could really make an impact for folks. Look, we have had people under an IRB, this is under a formal IRB program under compassionate use with long COVID, get the filter.

Now, my main disappointment for myself and our team is we don't have the spike protein up and running due to pre-post to show that they had it. No, they don't have it. But clinically, their brain fog is improved. Their fatigue is improved. And so clinically, we're seeing real benefit. And so this is a good first sign to really get after it.

Now, my main disappointment for myself and our team is we don't have the spike protein up and running due to pre-post to show that they had it. No, they don't have it. But clinically, their brain fog is improved. Their fatigue is improved. And so clinically, we're seeing real benefit. And so this is a good first sign to really get after it.

Now, my main disappointment for myself and our team is we don't have the spike protein up and running due to pre-post to show that they had it. No, they don't have it. But clinically, their brain fog is improved. Their fatigue is improved. And so clinically, we're seeing real benefit. And so this is a good first sign to really get after it.

And so, you know, we're a very small company, but we're getting after it.

And so, you know, we're a very small company, but we're getting after it.